Feldman Sheldon, Bansil Hannah, Ascherman Jeffrey, Grant Robert, Borden Billie, Henderson Peter, Ojo Adewuni, Taback Bret, Chen Margaret, Ananthakrishnan Preya, Vaz Amiya, Balci Fatih, Divgi Chaitanya R, Leung David, Rohde Christine
Division of Breast Surgery, Columbia University Medical Center, New York-Presbyterian Hospital, Columbia University, New York, NY, USA,
Ann Surg Oncol. 2015 Oct;22(10):3296-301. doi: 10.1245/s10434-015-4721-y. Epub 2015 Jul 23.
As many as 40 % of breast cancer patients undergoing axillary lymph node dissection (ALND) and radiotherapy develop lymphedema. We report our experience performing lymphatic-venous anastomosis using the lymphatic microsurgical preventive healing approach (LYMPHA) at the time of ALND. This technique was described by Boccardo, Campisi in 2009.
LYMPHA was offered to node-positive women with breast cancer requiring ALND. Afferent lymphatic vessels, identified by injection of blue dye in the ipsilateral arm, were sutured into a branch of the axillary vein distal to a competent valve. Follow-up was with pre- and postoperative lymphoscintigraphy, arm measurements, and (L-Dex®) bioimpedance spectroscopy.
Over 26 months, 37 women underwent attempted LYMPHA, with successful completion in 27. Unsuccessful attempts were due to lack of a suitable vein (n = 3) and lymphatic (n = 5) or extensive axillary disease (n = 1). There were no LYMPHA-related complications. Mean follow-up time was 6 months (range 3-24 months). Among completed patients, 10 (37%) had a body mass index of ≥30 kg/m(2) (mean 27.9 ± 6.8 kg/m(2), range 17.4-47.6 kg/m(2)), and 17 (63%) received axillary radiotherapy. Excluding two patients with preoperative lymphedema and those with less than 3-month follow-up, the lymphedema rate was 3 (12.5%) of 24 in successfully completed and 4 (50 %) of 8 in unsuccessfully treated patients.
Our transient lymphedema rate in this high-risk cohort of patients was 12.5%. Early data show that LYMPHA is feasible, safe, and effective for the primary prevention of breast cancer-related lymphedema.
在接受腋窝淋巴结清扫术(ALND)和放疗的乳腺癌患者中,多达40%会发生淋巴水肿。我们报告了在进行ALND时使用淋巴显微外科预防愈合方法(LYMPHA)进行淋巴管静脉吻合术的经验。该技术由博卡尔多、坎皮西于2009年描述。
LYMPHA应用于需要进行ALND的乳腺癌淋巴结阳性女性患者。通过向患侧手臂注射蓝色染料识别出输入淋巴管,将其缝合到腋静脉一个有功能瓣膜远端的分支中。通过术前和术后的淋巴闪烁显像、手臂测量以及(L-Dex®)生物电阻抗光谱法进行随访。
在26个月的时间里,37名女性尝试进行LYMPHA,其中27名成功完成。未成功的尝试原因包括缺乏合适的静脉(n = 3)、淋巴管(n = 5)或腋窝广泛病变(n = 1)。没有与LYMPHA相关的并发症。平均随访时间为6个月(范围3 - 24个月)。在完成手术的患者中,10名(37%)体重指数≥30 kg/m²(平均27.9 ± 6.8 kg/m²,范围17.4 - 47.6 kg/m²),17名(63%)接受了腋窝放疗。排除两名术前有淋巴水肿的患者以及随访时间少于3个月的患者,成功完成手术的24名患者中有3名(12.5%)发生淋巴水肿,未成功治疗的8名患者中有4名(50%)发生淋巴水肿。
在这个高危患者队列中,我们的短暂性淋巴水肿发生率为12.5%。早期数据表明,LYMPHA对于乳腺癌相关淋巴水肿的一级预防是可行、安全且有效的。